Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy

SARS-CoV-2 vaccinations were initially shown to substantially reduce risk of severe disease and death. However, pharmacokinetic (PK) waning and rapid viral evolution degrade neutralizing antibody (nAb) binding titers, causing loss of vaccinal protection. Additionally, there is inter-individual heter...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoddard, Madison, Yuan, Lin, Sarkar, Sharanya, Mangalaganesh, Shruthi, Nolan, Ryan P., Bottino, Dean, Hather, Greg, Hochberg, Natasha S., White, Laura F., Chakravarty, Arijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140995/
https://www.ncbi.nlm.nih.gov/pubmed/37112718
http://dx.doi.org/10.3390/vaccines11040806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140995/
https://www.ncbi.nlm.nih.gov/pubmed/37112718
http://dx.doi.org/10.3390/vaccines11040806

Ejemplares similares